Journal
CLINICAL INFECTIOUS DISEASES
Volume 47, Issue 12, Pages 1587-1592Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/593310
Keywords
-
Categories
Funding
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
- US Food and Drug Administration
- US Department of Health and Human Services
Ask authors/readers for more resources
Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available